- Home
- TLPH vs ANL Comparison
TLPH vs ANL Comparison
Compare TLPH & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TLPH | ANL |
|---|---|---|
| Founded | 2005 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 52.0M |
| IPO Year | 2011 | 2023 |
Fundamental Metrics
Financial Performance| Metric | TLPH | ANL |
|---|---|---|
| Price | $1.08 | $1.72 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 422.0K | 35.9K |
| Earning Date | 11-12-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,267.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.38 | $0.88 |
| 52 Week High | $1.57 | $2.99 |
Technical Indicators
Market Signals| Indicator | TLPH | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 64.96 |
| Support Level | $1.02 | $1.41 |
| Resistance Level | $1.22 | $1.61 |
| Average True Range (ATR) | 0.09 | 0.20 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 16.67 | 83.21 |
Price Performance
Historical ComparisonAbout TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.